Is Ipamorelin Banned in Sport? What the 2026 WADA List Says
Is ipamorelin banned in sport? Yes—for athletes subject to WADA-based anti-doping rules, ipamorelin is prohibited at all times. The 2026 World Anti-Doping Agency Prohibited List names ipamorelin under section S2.2.4 as a growth hormone secretagogue. The S2 class is prohibited both in and out of competition.
That answer is clear. A recent cycling announcement needs more careful wording. In August 2026, the International Testing Agency reported an adverse analytical finding for ipamorelin and imposed a provisional suspension. The agency also said the case remained underway. A laboratory finding and provisional suspension are important, but they are not the same as a final adjudication or final sanction.
Status note: The WADA rule and public case record in this article were checked on August 28, 2026. Anti-doping rules and ongoing case statuses can change.
Where does ipamorelin appear on WADA's 2026 Prohibited List?
WADA places ipamorelin in S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. More specifically, it appears under S2.2.4, which covers growth hormone-releasing factors. The list names ipamorelin among examples of growth hormone secretagogues and their mimetics.
The official 2026 list took effect on January 1, 2026. It says the full S2 category is:
- Prohibited at all times
- Applicable in and out of competition
- Classified as non-specified substances
The practical point is straightforward: an athlete covered by WADA-based rules should not read “out of competition” as a permitted window for ipamorelin.
What does “prohibited at all times” mean?
WADA defines “prohibited at all times” as prohibited in competition and out of competition. The rule is therefore not limited to the day of an event, a competition period, or a post-race test.
Anti-doping coverage is not identical for every person or organization. WADA's list applies through the rules adopted by Code signatories and relevant sports bodies. Athletes and support personnel should verify the rules that govern their specific federation, league, event, testing pool, or other organization rather than relying on a general web summary.
This article does not provide clearance-time, dosing, or testing-evasion guidance. Those details would not change the central rule: WADA expressly lists ipamorelin in a category prohibited at all times.
What does “non-specified substance” mean?
“Non-specified” is a classification used within the World Anti-Doping Code and results-management system. It should not be expanded into claims the list does not make.
In particular, the classification does not, by itself:
- Establish intent in an individual case
- Prove how a substance entered a sample
- Decide whether a defense or challenge will succeed
- Set the final sanction without the applicable results-management process
- Describe FDA approval, clinical safety, or research-use status
WADA status, FDA regulatory status, and a supplier's research-use restrictions are separate questions governed by different rules. A material labeled for laboratory research does not become permitted in sport because of that label.
What did the August 2026 cycling announcement say?
On August 21, 2026, the International Testing Agency announced that an out-of-competition sample collected from South African cyclist S’annara Grove on July 28 had returned an adverse analytical finding for ipamorelin. ITA said the sample was collected during a testing mission conducted in connection with the 2026 Commonwealth Games.
ITA reported that a mandatory provisional suspension had been imposed. It also stated that the rider had the right to challenge the provisional suspension and request that it be lifted. The announcement said the case was underway.
The distinction matters. As of August 28, the ITA's public UCI case table listed:
- A provisional suspension beginning August 20, 2026
- Case status as “On-going”
- No final period of ineligibility listed
- No disqualification listed
- No means of resolution listed
Those public facts do not support saying the rider received a final ban, admitted a violation, or was found guilty. They support the narrower statement that ITA reported an adverse analytical finding and imposed a provisional suspension while the case continued.
Why is an adverse analytical finding not a final ruling?
ITA describes an adverse analytical finding, or AAF, as a report from a WADA-accredited laboratory that establishes the presence of a prohibited substance, its metabolites or markers, or evidence of a prohibited method under the applicable laboratory standard.
An AAF can trigger notification, review, provisional measures, and the broader results-management process. That process can include challenges, hearings, and a decision about whether an anti-doping rule violation is established and which consequences apply.
That is why responsible reporting should use the terms in the official record:
- “Adverse analytical finding,” not “final positive ruling”
- “Provisionally suspended,” not “received a final ban”
- “Ongoing case,” not “found guilty”
The ITA notice is the primary source for the announcement, and its UCI case table is the best public status check cited here.
Does WADA status answer the scientific evidence question?
No. A prohibited-list classification is a sports-governance determination. It is not a clinical approval, a finding that a substance is safe or effective, or a substitute for reviewing the scientific literature.
For a separate look at published human and preclinical research, see our ipamorelin research evidence overview. Keeping those questions separate helps avoid two common errors: treating a sports rule as a clinical conclusion, or treating research literature as permission for use in sport.
JD BioWorks' own Prohibited Uses Policy and Research Use Disclaimer are also separate from WADA rules. They govern JD BioWorks materials and prohibit human or veterinary use; they do not determine an athlete's eligibility or anti-doping outcome.
What should athletes and research organizations take away?
For athletes subject to WADA-based rules, the safest conclusion is the simplest one: ipamorelin is expressly prohibited at all times under the 2026 list. Do not rely on informal descriptions, product labels, or social-media claims to determine eligibility.
Athletes and support personnel should consult the applicable anti-doping organization or federation for current rule and Therapeutic Use Exemption questions. Research organizations should keep sports-eligibility rules separate from laboratory documentation, study design, analytical identity, and research-use controls.
For more on how JD BioWorks evaluates evidence and separates established facts from inference, review our Scientific Sourcing and Editorial Standards and browse the Research Library.
Frequently asked questions
Is ipamorelin prohibited only during competition?
No. WADA classifies S2 substances as prohibited at all times, meaning both in and out of competition.
Is ipamorelin a specified substance?
No. WADA states that all prohibited substances in S2 are non-specified. That classification alone does not decide intent, defenses, or the final consequence in an individual case.
Is an adverse analytical finding the same as a final anti-doping violation?
No. An adverse analytical finding is a qualifying laboratory report. A final determination comes through the applicable results-management and adjudication process.
Has the August 2026 cycling case produced a final sanction?
Not according to the public ITA record checked on August 28, 2026. The rider was listed as provisionally suspended and the case as ongoing, with no final period of ineligibility or resolution shown.
Does a research-use label change ipamorelin's WADA status?
No. WADA's classification concerns the substance under anti-doping rules. JD BioWorks' research-use restrictions are a separate matter and do not make a substance permitted in sport.
Primary sources
- World Anti-Doping Agency: 2026 Prohibited List
- International Testing Agency: August 21, 2026 provisional-suspension announcement
- International Testing Agency: UCI public case table
- World Anti-Doping Agency: World Anti-Doping Code
Research-use and compliance disclaimer: This article provides general educational and research information based on sources reviewed August 28, 2026. It is not medical, legal, or anti-doping advice and does not determine eligibility, liability, sanction, or Therapeutic Use Exemption status. Anti-doping rules and ongoing case statuses can change; athletes and support personnel should verify current requirements with WADA and their applicable federation or anti-doping organization. JD BioWorks materials are for qualified laboratory research only and are not for human or veterinary use. Product availability or analytical documentation does not establish safety, efficacy, clinical suitability, or permission for use in sport.